{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:36:01Z","timestamp":1790130961223,"version":"4.0.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T00:00:00Z","timestamp":1662854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.cld.2022.06.009","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T20:50:58Z","timestamp":1666126258000},"page":"727-745","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Evaluation and Management of Pruritus in Primary Biliary Cholangitis"],"prefix":"10.1016","volume":"26","author":[{"given":"Miriam M.","family":"D\u00fcll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas E.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.cld.2022.06.009_bib1","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/bjd.17933","article-title":"Pruritus secondary to primary biliary cholangitis: a review of the pathophysiology and management with phototherapy","volume":"181","author":"Hussain","year":"2019","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.cld.2022.06.009_bib2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11894-019-0713-6","article-title":"Treatment of pruritus secondary to liver disease","volume":"21","author":"Dull","year":"2019","journal-title":"Curr Gastroenterol Rep"},{"issue":"1","key":"10.1016\/j.cld.2022.06.009_bib3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.26365","article-title":"Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study","volume":"58","author":"Mells","year":"2013","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"2","key":"10.1016\/j.cld.2022.06.009_bib4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11901-020-00517-x","article-title":"Newer approaches to the management of pruritus in cholestatic liver disease","volume":"19","author":"D\u00fcll","year":"2020","journal-title":"Curr Hepatol Rep"},{"key":"10.1016\/j.cld.2022.06.009_bib5","doi-asserted-by":"crossref","first-page":"639674","DOI":"10.3389\/fmed.2021.639674","article-title":"Cholestasis-associated pruritus and its pruritogens","volume":"8","author":"Langedijk","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"10.1016\/j.cld.2022.06.009_bib6","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1111\/exd.14024","article-title":"What are new treatment concepts in systemic itch?","volume":"28","author":"Kremer","year":"2019","journal-title":"Exp Dermatol"},{"issue":"4","key":"10.1016\/j.cld.2022.06.009_bib7","first-page":"643","article-title":"Pruritus and fatigue in primary biliary cirrhosis. Bailliere's best practice & research","volume":"14","author":"Bergasa","year":"2000","journal-title":"Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2022.06.009_bib8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2340\/00015555-0350","article-title":"Itch in primary biliary cirrhosis: a patients' perspective","volume":"88","author":"Rishe","year":"2008","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"10.1016\/j.cld.2022.06.009_bib9","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/gut.2003.023937","article-title":"Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort","volume":"53","author":"Prince","year":"2004","journal-title":"Gut"},{"issue":"15","key":"10.1016\/j.cld.2022.06.009_bib10","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.2165\/00003495-200868150-00006","article-title":"Pathogenesis and treatment of pruritus in cholestasis","volume":"68","author":"Kremer","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.cld.2022.06.009_bib11","doi-asserted-by":"crossref","first-page":"641163","DOI":"10.3389\/fmed.2021.641163","article-title":"Endogenous opioid levels do not correlate with itch intensity and therapeutic interventions in hepatic pruritus","volume":"8","author":"Dull","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"10.1016\/j.cld.2022.06.009_bib12","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/17474124.2021.1945919","article-title":"A\u00a0consensus integrated care pathway for patients with primary biliary cholangitis: a guideline-based approach to clinical care of patients","volume":"15","author":"Hirschfield","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2022.06.009_bib13","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/00042737-200111000-00022","article-title":"Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy","volume":"13","author":"Neuberger","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.009_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.sder.2011.04.009","article-title":"The itch of liver disease","volume":"30","author":"Bergasa","year":"2011","journal-title":"Semin Cutan Med Surg"},{"issue":"3","key":"10.1016\/j.cld.2022.06.009_bib15","first-page":"203","article-title":"Assessment of the visual analogue score in the evaluation of the pruritus of cholestasis","volume":"5","author":"Bergasa","year":"2017","journal-title":"J\u00a0Clin Transl Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2022.06.009_bib16","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.jhep.2005.09.004","article-title":"The pruritus of cholestasis","volume":"43","author":"Bergasa","year":"2005","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2022.06.009_bib17","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jhep.2021.04.055","article-title":"An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs","volume":"75","author":"Cordell","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2022.06.009_bib18","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.cgh.2018.12.007","article-title":"Pruritus is common and undertreated in patients with primary biliary cholangitis in the United Kingdom","volume":"17","author":"Hegade","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2022.06.009_bib19","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1572-0241.2006.00423.x","article-title":"Dermatological manifestations in primary biliary cirrhosis patients: a case control study","volume":"101","author":"Koulentaki","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.009_bib20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL Clinical Practice Guidelines: management of cholestatic liver diseases","volume":"51","author":"European Association for the Study of the","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2022.06.009_bib21","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1016\/S0168-8278(18)30648-2","article-title":"Pruritus strongly reduces quality of life in PBC patients - real life data from a large national survey","volume":"68","author":"Honig","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2022.06.009_bib22","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2022.06.009_bib23","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1152\/physrev.00017.2019","article-title":"Physiology and pathophysiology of itch","volume":"100","author":"Cevikbas","year":"2019","journal-title":"Physiol Rev"},{"issue":"1","key":"10.1016\/j.cld.2022.06.009_bib24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-genet-120116-024723","article-title":"Mas-related G protein\u2013coupled receptors and the biology of itch sensation","volume":"51","author":"Meixiong","year":"2017","journal-title":"Annu Rev Genet"},{"issue":"3","key":"10.1016\/j.cld.2022.06.009_bib25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.det.2018.02.008","article-title":"Management of chronic hepatic itch","volume":"36","author":"Dull","year":"2018","journal-title":"Dermatol Clin"},{"issue":"Suppl 2","key":"10.1016\/j.cld.2022.06.009_bib26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000440829","article-title":"Pathogenesis and management of pruritus in PBC and PSC","volume":"33","author":"Kremer","year":"2015","journal-title":"Dig Dis (Basel, Switzerland)"},{"key":"10.1016\/j.cld.2022.06.009_bib27","doi-asserted-by":"crossref","first-page":"e44116","DOI":"10.7554\/eLife.44116","article-title":"Identification of a bilirubin receptor that may mediate a component of cholestatic itch","volume":"8","author":"Meixiong","year":"2019","journal-title":"eLife"},{"issue":"21","key":"10.1016\/j.cld.2022.06.009_bib28","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1073\/pnas.1903316116","article-title":"MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus","volume":"116","author":"Meixiong","year":"2019","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"S1","key":"10.1016\/j.cld.2022.06.009_bib29","first-page":"769A","article-title":"Bile salt subspecies activate the G protein-coupled receptor MRGX4 expressed on sensory neurons and cause itching in humans","volume":"70","author":"Wolf","year":"2019","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.cld.2022.06.009_bib30","doi-asserted-by":"crossref","first-page":"e48431","DOI":"10.7554\/eLife.48431","article-title":"MRGPRX4 is a bile acid receptor for human cholestatic itch","volume":"8","author":"Yu","year":"2019","journal-title":"eLife"},{"issue":"2","key":"10.1016\/j.cld.2022.06.009_bib31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/nn.3289","article-title":"A\u00a0subpopulation of nociceptors specifically linked to itch","volume":"16","author":"Han","year":"2013","journal-title":"Nat Neurosci"},{"issue":"5","key":"10.1016\/j.cld.2022.06.009_bib32","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A\u00a0randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"7","key":"10.1016\/j.cld.2022.06.009_bib33","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.cld.2022.06.009_bib34","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1572-0241.2007.01200.x","article-title":"The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis- associated pruritus","volume":"102","author":"Tandon","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2022.06.009_bib35","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2022.06.009_bib36","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1600-0676.1996.tb00749.x","article-title":"Hepatic concentrations of proenkephalin-derived opioids are increased in a rat model of cholestasis","volume":"16","author":"Bergasa","year":"1996","journal-title":"Liver"},{"issue":"11","key":"10.1016\/j.cld.2022.06.009_bib37","first-page":"2028","article-title":"Methionine-enkephalin concentrations correlate with stage of disease but not pruritus in patients with primary biliary cirrhosis","volume":"89","author":"Spivey","year":"1994","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.009_bib38","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/0016-5085(92)90857-U","article-title":"Endogenous opioids accumulate in plasma in a rat model of acute cholestasis","volume":"103","author":"Swain","year":"1992","journal-title":"Gastroenterology"},{"issue":"6662","key":"10.1016\/j.cld.2022.06.009_bib39","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1136\/bmj.297.6662.1501","article-title":"Opioid peptides and primary biliary cirrhosis","volume":"297","author":"Thornton","year":"1988","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.cld.2022.06.009_bib40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1034\/j.1600-0676.2002.01458.x","article-title":"Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis","volume":"22","author":"Bergasa","year":"2002","journal-title":"Liver"},{"issue":"2","key":"10.1016\/j.cld.2022.06.009_bib41","doi-asserted-by":"crossref","first-page":"G346","DOI":"10.1152\/ajpgi.1995.268.2.G346","article-title":"Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver","volume":"268","author":"Bergasa","year":"1995","journal-title":"Am J Physiol Gastrointestinal Liver Physiol"},{"issue":"4","key":"10.1016\/j.cld.2022.06.009_bib42","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.25748","article-title":"Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions","volume":"56","author":"Kremer","year":"2012","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"10.1016\/j.cld.2022.06.009_bib43","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1053\/j.gastro.2010.05.009","article-title":"Lysophosphatidic acid is a potential mediator of cholestatic pruritus","volume":"139","author":"Kremer","year":"2010","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2022.06.009_bib44","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/flgastro-2015-100618","article-title":"A\u00a0systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis","volume":"7","author":"Hegade","year":"2016","journal-title":"Frontline Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2022.06.009_bib45","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2022.06.009_bib46","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2340\/00015555-3164","article-title":"European S2k guideline on chronic pruritus","volume":"99","author":"Weisshaar","year":"2019","journal-title":"Acta Derm Venereol."},{"issue":"7","key":"10.1016\/j.cld.2022.06.009_bib47","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2340\/00015555-3158","article-title":"Validation of a comprehensive set of pruritus assessment instruments: the chronic pruritus tools questionnaire PRURITOOLS","volume":"99","author":"Verweyen","year":"2019","journal-title":"Acta Derm Venereol."},{"issue":"2","key":"10.1016\/j.cld.2022.06.009_bib48","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clinre.2010.10.007","article-title":"Pathophysiology and current management of pruritus in liver disease","volume":"35","author":"Kremer","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2022.06.009_bib49","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"2","key":"10.1016\/j.cld.2022.06.009_bib50","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2362.2000.00606.x","article-title":"Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man","volume":"30","author":"Rust","year":"2000","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"10.1016\/j.cld.2022.06.009_bib51","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/hep.23821","article-title":"The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Kuiper","year":"2010","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"8","key":"10.1016\/j.cld.2022.06.009_bib52","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1478-3231.2006.01326.x","article-title":"Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials","volume":"26","author":"Khurana","year":"2006","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.cld.2022.06.009_bib53","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/liv.14069","article-title":"Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus","volume":"39","author":"Hegade","year":"2019","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.cld.2022.06.009_bib54","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/0016-5085(92)90335-V","article-title":"Effects of long-term rifampicin administration in primary biliary cirrhosis","volume":"102","author":"Bachs","year":"1992","journal-title":"Gastroenterology"},{"issue":"8638","key":"10.1016\/j.cld.2022.06.009_bib55","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0140-6736(89)91608-5","article-title":"Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis","volume":"1","author":"Bachs","year":"1989","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.cld.2022.06.009_bib56","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jhepr.2019.05.005","article-title":"New treatments\/targets for primary biliary cholangitis","volume":"1","author":"Corpechot","year":"2019","journal-title":"JHEP Rep"},{"issue":"2","key":"10.1016\/j.cld.2022.06.009_bib57","doi-asserted-by":"crossref","first-page":"e87327","DOI":"10.1371\/journal.pone.0087327","article-title":"Regulation of fatty acid oxidation in mouse cumulus-oocyte complexes during maturation and modulation by PPAR agonists","volume":"9","author":"Dunning","year":"2014","journal-title":"PloS one"},{"issue":"6","key":"10.1016\/j.cld.2022.06.009_bib58","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00535-014-0998-z","article-title":"Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA","volume":"50","author":"Tanaka","year":"2015","journal-title":"J\u00a0Gastroenterol"},{"issue":"23","key":"10.1016\/j.cld.2022.06.009_bib59","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A\u00a0placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.cld.2022.06.009_bib60","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2021.04.010","article-title":"Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis","volume":"75","author":"Tanaka","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2022.06.009_bib61","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0168-8278(02)00318-5","article-title":"Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo- controlled study","volume":"37","author":"Terg","year":"2002","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2022.06.009_bib62","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/gast.1997.v113.pm9322521","article-title":"Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study","volume":"113","author":"Wolfhagen","year":"1997","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cld.2022.06.009_bib63","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3748\/wjg.v12.i7.1125","article-title":"Effect of oral naltrexone on pruritus in cholestatic patients","volume":"12","author":"Mansour-Ghanaei","year":"2006","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2022.06.009_bib64","first-page":"1022","article-title":"Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease","volume":"91","author":"Carson","year":"1996","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.009_bib65","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0016-5085(03)00879-5","article-title":"Pain as a complication of use of opiate antagonists for symptom control in cholestasis","volume":"125","author":"McRae","year":"2003","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2022.06.009_bib66","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","article-title":"Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study","volume":"25","author":"Kumagai","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1016\/j.cld.2022.06.009_bib67","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1681\/ASN.2005020152","article-title":"Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies","volume":"16","author":"Wikstrom","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.cld.2022.06.009_bib68","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/hepr.12830","article-title":"Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double- blind trial","volume":"47","author":"Kumada","year":"2017","journal-title":"Hepatol Res"},{"issue":"3","key":"10.1016\/j.cld.2022.06.009_bib69","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1912770","article-title":"A\u00a0phase 3 trial of difelikefalin in hemodialysis patients with pruritus","volume":"382","author":"Fishbane","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.cld.2022.06.009_bib70","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s40265-021-01619-6","article-title":"Difelikefalin: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.cld.2022.06.009_bib71","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000450988","article-title":"Apical sodium-dependent transporter inhibitors in primary biliary cholangitis and primary sclerosing cholangitis","volume":"35","author":"Hegade","year":"2017","journal-title":"Dig Dis (Basel, Switzerland)"},{"issue":"1","key":"10.1016\/j.cld.2022.06.009_bib72","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12876-016-0481-9","article-title":"BAT117213: ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial","volume":"16","author":"Hegade","year":"2016","journal-title":"BMC Gastroenterol"},{"issue":"10074","key":"10.1016\/j.cld.2022.06.009_bib73","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study","volume":"389","author":"Hegade","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cld.2022.06.009_bib74","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40265-021-01649-0","article-title":"Maralixibat: first approval","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs"},{"issue":"10311","key":"10.1016\/j.cld.2022.06.009_bib75","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(21)01256-3","article-title":"Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study","volume":"398","author":"Gonzales","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.cld.2022.06.009_bib76","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hep4.1305","article-title":"A\u00a0randomized, controlled, phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis","volume":"3","author":"Mayo","year":"2019","journal-title":"Hepatol Commun"},{"issue":"5","key":"10.1016\/j.cld.2022.06.009_bib77","doi-asserted-by":"crossref","first-page":"101751","DOI":"10.1016\/j.clinre.2021.101751","article-title":"Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: phase 2 study","volume":"45","author":"Baumann","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"15","key":"10.1016\/j.cld.2022.06.009_bib78","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s40265-021-01594-y","article-title":"Odevixibat: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.cld.2022.06.009_bib79","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1111\/j.1572-0241.2003.08662.x","article-title":"Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis","volume":"98","author":"Browning","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2022.06.009_bib80","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep.21553","article-title":"Sertraline as a first- line treatment for cholestatic pruritus","volume":"45","author":"Mayo","year":"2007","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"6","key":"10.1016\/j.cld.2022.06.009_bib81","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.jpainsymman.2003.05.004","article-title":"Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial","volume":"26","author":"Zylicz","year":"2003","journal-title":"J Pain Symptom Manag"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326122000472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326122000472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:59:27Z","timestamp":1761069567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326122000472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1089326122000472"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2022.06.009","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation and Management of Pruritus in Primary Biliary Cholangitis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2022.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}